Elena Pope

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3418542/publications.pdf

Version: 2024-02-01

185 papers	7,000 citations	42 h-index	76 76 g-index
191	191	191	6369 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	13.9	892
2	A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. New England Journal of Medicine, 2015, 372, 735-746.	13.9	601
3	Consensus-Derived Practice Standards Plan for Complicated Kaposiform Hemangioendothelioma. Journal of Pediatrics, 2013, 163, 285-291.	0.9	224
4	PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. Journal of Pediatrics, 2016, 178, 24-33.e2.	0.9	186
5	Timolol Maleate 0.5% or 0.1% Gelâ€Forming Solution for Infantile Hemangiomas: A Retrospective, Multicenter, Cohort Study. Pediatric Dermatology, 2012, 29, 28-31.	0.5	172
6	A consensus approach to wound care in epidermolysis bullosa. Journal of the American Academy of Dermatology, 2012, 67, 904-917.	0.6	148
7	The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures. Journal of Rheumatology, 2009, 36, 2819-2829.	1.0	147
8	Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. Pediatrics, 2011, 128, 723-728.	1.0	139
9	Development of consensus treatment plans for juvenile localized scleroderma: A roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care and Research, 2012, 64, 1175-1185.	1.5	137
10	Topical Timolol Gel for Infantile Hemangiomas: A Pilot Study. Archives of Dermatology, 2010, 146, 564-5.	1.7	134
11	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 38-69.	2.0	134
12	Stroke in Children With Posterior Fossa Brain Malformations, Hemangiomas, Arterial Anomalies, Coarctation of the Aorta and Cardiac Defects, and Eye Abnormalities (PHACE) Syndrome. Stroke, 2012, 43, 1672-1674.	1.0	112
13	Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon. Pediatric Blood and Cancer, 2012, 59, 934-938.	0.8	107
14	Oral Versus High-Dose Pulse Corticosteroids for Problematic Infantile Hemangiomas: A Randomized, Controlled Trial. Pediatrics, 2007, 119, e1239-e1247.	1.0	96
15	Topical imiquimod in the treatment of infantile hemangiomas: A retrospective study. Journal of the American Academy of Dermatology, 2007, 56, 63-68.	0.6	92
16	Dermatological Complications of Continuous Subcutaneous Insulin Infusion in Children and Adolescents. Journal of Pediatrics, 2008, 152, 622-628.	0.9	92
17	Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 2016, 138, .	1.0	92
18	Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics, 2016, 137, .	1.0	88

#	Article	IF	Citations
19	Mycosis Fungoides in the Pediatric Population: Report from an International Childhood Registry of Cutaneous Lymphoma. Journal of Cutaneous Medicine and Surgery, 2010, 14, 1-6.	0.6	79
20	A double-blind, randomized, placebo-controlled trial of topical tacrolimus $0\hat{A}\cdot1\%$ vs. clobetasol propionate $0\hat{A}\cdot05\%$ in childhood vitiligo. British Journal of Dermatology, 2011, 165, 626-632.	1.4	69
21	Hidradenitis suppurativa in the pediatric population. Journal of the American Academy of Dermatology, 2015, 73, S36-S41.	0.6	67
22	Trichodysplasia spinulosa is characterized by active polyomavirus infection. Journal of Clinical Virology, 2012, 53, 225-230.	1.6	66
23	Finasteride for the Treatment of Hidradenitis Suppurativa in Children and Adolescents. JAMA Dermatology, 2013, 149, 732.	2.0	66
24	En Coup de Sabre Scleroderma and Parry-Romberg Syndrome in Adolescents: Surgical Options and Patient-related Outcomes. Journal of Rheumatology, 2010, 37, 2174-2179.	1.0	65
25	Congenital Cardiac, Aortic Arch, and Vascular Bed Anomalies in PHACE Syndrome (from the) Tj ETQq1 1 0.784314	4 rgBT /O\ 0.7	verlock 10 Tf
26	Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. British Journal of Dermatology, 2013, 168, 222-224.	1.4	65
27	Pemoline-associated fulminant liver failure: Testing the evidence for causation. Clinical Pharmacology and Therapeutics, 1995, 57, 696-698.	2.3	64
28	Childhood acquired lipodystrophy: AÂretrospectiveÂstudy. Journal of the American Academy of Dermatology, 2006, 55, 947-950.	0.6	62
29	High-potency steroid use in children with vitiligo: A retrospective study. Journal of the American Academy of Dermatology, 2007, 56, 236-241.	0.6	62
30	Amniotic membrane use in dermatology. International Journal of Dermatology, 2009, 48, 935-940.	0.5	61
31	Infliximabâ€Induced Psoriasis and Psoriasiform Skin Lesions in Pediatric Crohn Disease and a Potential Association With ILâ€23 Receptor Polymorphisms. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 512-518.	0.9	61
32	Kasabach–Merritt phenomenon: a single centre experience. European Journal of Haematology, 2010, 84, 97-104.	1.1	60
33	Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. British Journal of Dermatology, 2015, 172, 13-23.	1.4	60
34	Relapse after systemic treatment in paediatric morphoea. British Journal of Dermatology, 2012, 166, 443-445.	1.4	54
35	Childhood Mycosis Fungoides: Experience of 28 Patients and Response to Phototherapy. Pediatric Dermatology, 2014, 31, 459-464.	0.5	53
36	Incontinentia Pigmenti in Boys: A Series and Review of the Literature. Pediatric Dermatology, 2006, 23, 523-527.	0.5	50

#	Article	IF	CITATIONS
37	Trichodysplasia Spinulosa-A Rare Complication in Immunosuppressed Patients. Pediatric Dermatology, 2010, 27, 509-513.	0.5	50
38	Identification of major clonal complexes and toxin producing strains among Staphylococcus aureus associated with atopic dermatitis. Microbes and Infection, 2011, 13, 189-197.	1.0	50
39	Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children. JAMA Dermatology, 2014, 150, 47.	2.0	49
40	Prevalence and Characterization of Pruritus in Epidermolysis Bullosa. Pediatric Dermatology, 2015, 32, 53-59.	0.5	49
41	Topical Imiquimod 5% Cream for Pediatric Plaque Morphea: A Prospective, Multiple-Baseline, Open-Label Pilot Study. Dermatology, 2011, 223, 363-369.	0.9	48
42	A comparison of disease severity among affectedÂmaleÂversus female patients with PHACEÂsyndrome. Journal of the American Academy of Dermatology, 2008, 58, 81-87.	0.6	46
43	Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth viaÂCancer Genomics. Journal of Investigative Dermatology, 2018, 138, 957-967.	0.3	45
44	Diagnosis and Management of Atopic Dermatitis: A Review. Advances in Skin and Wound Care, 2018, 31, 538-550.	0.5	41
45	Generalized petechial eruption induced by parvovirus B19 infection. Journal of the American Academy of Dermatology, 2005, 52, S109-S113.	0.6	40
46	Colonization with communityâ€acquired methicillinâ€resistant <i>Staphylococcus aureus</i> in children with atopic dermatitis: a crossâ€sectional study. International Journal of Dermatology, 2011, 50, 682-688.	0.5	39
47	A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics. Pediatric Dermatology, 2014, 31, 430-439.	0.5	39
48	Dilated Cardiomyopathy in Epidermolysis Bullosa: A Retrospective, Multicenter Study. Pediatric Dermatology, 2010, 27, 238-243.	0.5	37
49	The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study. Journal of the American Academy of Dermatology, 2017, 76, 1084-1087.	0.6	37
50	Hidradenitis Suppurativa in the Pediatric Population. JAMA Dermatology, 2021, 157, 385.	2.0	36
51	Management of pediatric plaque psoriasis using biologics. Journal of the American Academy of Dermatology, 2020, 82, 213-221.	0.6	32
52	Vincristine and Corticosteroids as First-Line Treatment of Kasabach-Merritt Syndrome in Kaposiform Hemangioendothelioma. Journal of Cutaneous Medicine and Surgery, 2009, 13, 155-159.	0.6	31
53	Polyomavirus-Associated Trichodysplasia Spinulosa Involves Hyperproliferation, pRB Phosphorylation and Upregulation of p16 and p21. PLoS ONE, 2014, 9, e108947.	1.1	31
54	Eczema Herpeticum in Children: Clinical Features and Factors Predictive of Hospitalization. Journal of Pediatrics, 2012, 161, 671-675.	0.9	29

#	Article	IF	Citations
55	Epidermolysis Bullosa Pruriginosa: A Systematic Review Exploring Genotype–Phenotype Correlation. American Journal of Clinical Dermatology, 2015, 16, 81-87.	3.3	29
56	Primary Cutaneous Lymphomas in Children and Adolescents. Pediatric Blood and Cancer, 2016, 63, 1886-1894.	0.8	29
57	Effects of Vitamin D levels and supplementation on atopic dermatitis: A systematic review. Pediatric Dermatology, 2018, 35, 754-760.	0.5	29
58	Evaluation of Treatments for Pruritus in Epidermolysis Bullosa. Pediatric Dermatology, 2015, 32, 628-634.	0.5	28
59	Management of infantile hemangiomas during the COVID pandemic. Pediatric Dermatology, 2020, 37, 412-418.	0.5	28
60	Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. JAMA Dermatology, 2019, 155, 196.	2.0	27
61	Late growth of infantile hemangiomas in children >3Âyears of age: A retrospective study. Journal of the American Academy of Dermatology, 2019, 80, 493-499.	0.6	27
62	Amniotic membrane grafting in patients with epidermolysis bullosa with chronic wounds. Journal of the American Academy of Dermatology, 2010, 62, 1038-1044.	0.6	26
63	Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa: A Consensusâ€Generated Clinical Research Tool. Pediatric Dermatology, 2015, 32, 41-52.	0.5	26
64	Copy Number Variation Analysis in 98 Individuals with PHACE Syndrome. Journal of Investigative Dermatology, 2013, 133, 677-684.	0.3	25
65	Retrospective Review of Relapse after Systemic Cyclosporine in Children with Atopic Dermatitis. Pediatric Dermatology, 2015, 32, 36-40.	0.5	25
66	Impact of Cosmetic Camouflage on the Quality of Life of Children With Skin Disease and Their Families. Journal of Cutaneous Medicine and Surgery, 2016, 20, 211-215.	0.6	25
67	Multifocal lymphangioendotheliomatosis with thrombocytopenia. Journal of the American Academy of Dermatology, 2006, 54, S214-S217.	0.6	24
68	Pancreatic Panniculitis in a 4â€yearâ€old Child with Nephrotic Syndrome. Pediatric Dermatology, 2007, 24, 659-660.	0.5	24
69	Erythema Multiforme in Children and <i>Mycoplasma pneumoniae</i> Aetiology. Journal of Cutaneous Medicine and Surgery, 2016, 20, 453-457.	0.6	24
70	New Features for Measuring Disease Activity in Pediatric Localized Scleroderma. Journal of Rheumatology, 2018, 45, 1680-1688.	1.0	24
71	Vitamin D Level and Supplementation in Pediatric Atopic Dermatitis: A Randomized Controlled Trial. Journal of Cutaneous Medicine and Surgery, 2019, 23, 44-49.	0.6	24
72	Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma. JAMA Pediatrics, 2022, 176, 34.	3.3	24

#	Article	IF	Citations
73	Principles of Wound Care in Patients with Epidermolysis Bullosa. Pediatric Dermatology, 2010, 27, 229-237.	0.5	23
74	Staphylococcal scalded skin syndrome: An epidemiological and clinical review of 84 cases. Pediatric Dermatology, 2021, 38, 149-153.	0.5	23
75	Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma. JAMA Dermatology, 2021, 157, 566.	2.0	23
76	Vincristine for Successful Treatment of Steroid-Dependent Infantile Hemangiomas. Pediatrics, 2015, 135, e1501-e1505.	1.0	22
77	Pediatric Psychocutaneous Disorders. American Journal of Clinical Dermatology, 2011, 12, 247-257.	3.3	21
78	Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. Journal of Pediatrics, 2019, 211, 152-158.	0.9	21
79	Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. Journal of Rheumatology, 2020, 47, 1242-1252.	1.0	21
80	Propranolol in the Management of Infantile Hemangiomas: Clinical Response and Predictors. Journal of Cutaneous Medicine and Surgery, 2012, 16, 169-173.	0.6	20
81	Diagnosis and Management of Morphea and Lichen Sclerosus and Atrophicus in Children. Pediatric Clinics of North America, 2014, 61, 309-319.	0.9	20
82	Eruptive pyogenic granulomas developing after drug hypersensitivity reaction. Journal of the American Academy of Dermatology, 2009, 60, 855-857.	0.6	19
83	Predisposing Factors and Outcomes of Malignant Skin Tumors in Children. Plastic and Reconstructive Surgery, 2010, 126, 508-514.	0.7	19
84	Bullous Henoch-Schönlein Purpura in Children: A Report of 6 Cases and Review of the Literature. Clinical Pediatrics, 2010, 49, 1033-1037.	0.4	19
85	New insights into pustular dermatoses in pediatricÂpatients. Journal of the American Academy of Dermatology, 2014, 70, 767-773.	0.6	19
86	Kaposiform Hemangioendothelioma Presenting Antenatally With a Pericardial Effusion. Journal of Pediatric Hematology/Oncology, 2008, 30, 761-763.	0.3	18
87	Yellow Nail Syndrome. Pediatric Dermatology, 2010, 27, 675-676.	0.5	18
88	Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma. Current Opinion in Pediatrics, 2007, 19, 441-445.	1.0	17
89	Development of a disease severity score for newborns with collodion membrane. Journal of the American Academy of Dermatology, 2014, 70, 506-511.	0.6	17
90	Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB). British Journal of Dermatology, 2018, 178, 1128-1134.	1.4	17

#	Article	IF	CITATIONS
91	Cutaneous sequelae in neonatal lupus: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 83, 440-446.	0.6	17
92	Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatric Dermatology, 2021, 38, 119-124.	0.5	17
93	Drugs and Sexual Assault. Trauma, Violence, and Abuse, 2001, 2, 51-55.	3.9	16
94	The role of infrared thermography in evaluation of proliferative infantile hemangiomas. Results of a pilot study. International Journal of Dermatology, 2014, 53, e216-7.	0.5	16
95	Infrared Thermography to Assess Proliferation and Involution of Infantile Hemangiomas. JAMA Dermatology, 2014, 150, 964.	2.0	16
96	Systematic review of cases of cutaneous T-cell lymphoma transformation in pityriasis lichenoides and small plaque parapsoriasis. British Journal of Dermatology, 2016, 175, 807-809.	1.4	16
97	Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma. Rheumatology, 2021, 60, 5724-5733.	0.9	16
98	Involvement of three mucous membranes in herpes-induced recurrent erythema multiforme. Journal of the American Academy of Dermatology, 2005, 52, 171-172.	0.6	15
99	Childhood Psoriasis Treatment: Evidence Published Over the Last 5 Years. Reviews on Recent Clinical Trials, 2011, 6, 36-43.	0.4	15
100	Natural history and extracutaneous involvement of congenital morphea: Multicenter retrospective cohort study and literature review. Pediatric Dermatology, 2018, 35, 761-768.	0.5	15
101	Unraveling incontinentia pigmenti: A comparison of phenotype and genotype variants. Journal of the American Academy of Dermatology, 2019, 81, 1142-1149.	0.6	15
102	The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: AÂfeasibility trial. Journal of the American Academy of Dermatology, 2012, 66, 264-270.	0.6	14
103	Neurocutaneous melanosis and congenital melanocytic naevi: a retrospective review of clinical and radiological characteristics. British Journal of Dermatology, 2015, 173, 1522-1524.	1.4	14
104	Localized infantile hemangiomas of the face and scalp: Predilection for the midline and periorbital and perioral skin. Pediatric Dermatology, 2018, 35, 774-779.	0.5	14
105	Acral Changes in pediatric patients during COVID 19 pandemic: Registry report from the COVID 19 response task force of the society of pediatric dermatology (SPD) and pediatric dermatology research alliance (PeDRA). Pediatric Dermatology, 2021, 38, 364-370.	0.5	14
106	Primitive Myxoid Mesenchymal Tumor of Infancy in a Preterm Infant. Pediatric Dermatology, 2010, 27, 635-637.	0.5	13
107	Dilated Cardiomyopathy in Epidermolysis Bullosa. Dermatologic Clinics, 2010, 28, 347-351.	1.0	13
108	Epidermolysis Bullosa Pruriginosa. International Journal of Lower Extremity Wounds, 2015, 14, 196-199.	0.6	13

#	Article	IF	CITATIONS
109	Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases. Clinical Drug Investigation, 2020, 40, 293-304.	1.1	13
110	Cutaneous poisoning syndromes in children: a review. Current Opinion in Pediatrics, 2006, 18, 410-416.	1.0	12
111	Chronic Urticaria in Children. Clinical Pediatrics, 2009, 48, 351-355.	0.4	12
112	The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity. International Journal of Dermatology, 2017, 56, 63-67.	0.5	12
113	Children with facial morphoea managing everyday life: a qualitative study. British Journal of Dermatology, 2018, 179, 353-361.	1.4	11
114	A retrospective multicenter study of fatal pediatric melanoma. Journal of the American Academy of Dermatology, 2020, 83, 1274-1281.	0.6	11
115	Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensusâ€based guidance for clinical decisionâ€making during the COVIDâ€19 pandemic. Pediatric Dermatology, 2020, 37, 424-434.	0.5	11
116	A novel fibrotic disorder associated with increased dermal fibroblast proliferation and downregulation of genes of the microfibrillar network. British Journal of Dermatology, 2010, 163, 1102-1115.	1.4	10
117	Correlation of clinical tools to determine activity of localized scleroderma in paediatric patients. British Journal of Dermatology, 2016, 174, 408-410.	1.4	10
118	Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. Pediatric Rheumatology, 2019, 17, 43.	0.9	10
119	Blistering severe cutaneous adverse reactions in children: proposal for paediatricâ€focused clinical criteria. British Journal of Dermatology, 2021, 185, 447-449.	1.4	10
120	Salivary Measurement of Deferiprone Concentrations and Correlation with Serum Levels. Therapeutic Drug Monitoring, 1997, 19, 95-97.	1.0	10
121	Epidermolysis Bullosa and Chronic Wounds. Advances in Skin and Wound Care, 2013, 26, 177-188.	0.5	9
122	Oral Nadolol for the Treatment of Infantile Hemangiomas: A Singleâ€Institution Retrospective Cohort Study. Pediatric Dermatology, 2015, 32, 690-695.	0.5	9
123	Hematopoietic stem cell transplantation for RelB deficiency. Journal of Allergy and Clinical Immunology, 2017, 140, 1199-1201.e3.	1.5	9
124	Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database. Pediatric Dermatology, 2020, 37, 326-332.	0.5	9
125	Percutaneous Interventional Radiology Procedures in Patients With Epidermolysis Bullosa: Modifications and Challenges. American Journal of Roentgenology, 2010, 195, 468-475.	1.0	8
126	Postmortem Vascular Pathology in PHACES Syndrome: A Case Report. Pediatric and Developmental Pathology, 2012, 15, 507-510.	0.5	8

#	Article	IF	CITATIONS
127	Discordance of pediatric morphea treatment by pediatric dermatologists. Pediatric Dermatology, 2018, 35, 47-54.	0.5	8
128	Generation of High-Titer Self-Inactivated \hat{I}^3 -Retroviral Vector Producer Cells. Molecular Therapy - Methods and Clinical Development, 2019, 14, 90-99.	1.8	8
129	Feasibility of Using Elastography Ultrasound in Pediatric Localized Scleroderma (Morphea). Ultrasound in Medicine and Biology, 2020, 46, 3218-3227.	0.7	8
130	Peel Test to Assess the Adhesion Strength of the Dermal–Epidermal Junction in Tissue-Engineered Skin. Tissue Engineering - Part C: Methods, 2020, 26, 180-189.	1.1	8
131	Association of Demographic Factors and Infantile Hemangioma Characteristics With Risk of PHACE Syndrome. JAMA Dermatology, 2021, 157, 932.	2.0	8
132	A Chromosomal Duplication Encompassing Interleukin-33 Causes a Novel Hyper IgE Phenotype Characterized by Eosinophilic Esophagitis and Generalized Autoimmunity. Gastroenterology, 2022, 163, 510-513.e3.	0.6	8
133	Sporotrichoid Aspergillosis in an Immunocompromised Child: A Case Report and Review of the Literature. Pediatric Dermatology, 2009, 26, 592-596.	0.5	7
134	Tropical Skin Diseases in Children: A Reviewâ€"Part II. Pediatric Dermatology, 2016, 33, 264-274.	0.5	7
135	Mosaic Neurofibromatosis Type 1 in Children: A Single-Institution Experience. Journal of Cutaneous Medicine and Surgery, 2017, 21, 379-382.	0.6	7
136	Isolated cutaneous mucormycosis in a pediatric renal transplant recipient. Pediatric Transplantation, 2018, 22, e13172.	0.5	7
137	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemicâ€"Consensus: Recommendations by an international panel of experts. Journal of the American Academy of Dermatology, 2020, 83, 1222-1224.	0.6	7
138	Characterization of vascular stains associated with high flow. Journal of the American Academy of Dermatology, 2021, 84, 654-660.	0.6	7
139	The use of rapamycin to treat vascular tumours and malformations: A single-centre experience. Paediatrics and Child Health, 2021, 26, e25-e32.	0.3	7
140	Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations. Journal of the American Academy of Dermatology, 2021, 85, 38-45.	0.6	7
141	Adie Pupil as the Initial Presentation of Localized En Coup de Sabre Scleroderma. Journal of Rheumatology, 2017, 44, 1096-1097.	1.0	6
142	Genotype-phenotype data from a case series of patients with mosaic neurofibromatosis type 1. British Journal of Dermatology, 2018, 179, 1216-1217.	1.4	6
143	Sinecatechins ointment for the treatment of warts in children. Pediatric Dermatology, 2019, 36, 121-124.	0.5	6
144	Outcomes and Predictors for Reâ€stenosis of Esophageal Stricture in Epidermolysis Bullosa. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 310-314.	0.9	6

#	Article	IF	Citations
145	Epidermolysis bullosa: a 2020 perspective. British Journal of Dermatology, 2020, 183, 603-603.	1.4	6
146	Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. International Journal of Pediatric Otorhinolaryngology, 2021, 144, 110688.	0.4	6
147	Psychosocial impact of epidermolysis bullosa on patients: A qualitative study. Pediatric Dermatology, 2021, 38, 819-824.	0.5	6
148	Impediments to Research in Pediatric Dermatology: The Results of a Survey of the Members of the Society for Pediatric Dermatology. Pediatric Dermatology, 2010, 27, 337-340.	0.5	5
149	Epidermolysis Bullosa Care in Canada. Dermatologic Clinics, 2010, 28, 391-392.	1.0	5
150	Abnormal hemostasis in children with vascular anomalies, part I: Thrombocytopenias among different vascular anomalies. Thrombosis Research, 2020, 196, 626-634.	0.8	5
151	A novel <i>ENPP1</i> mutation identified in a multigenerational family affected by Cole disease. Pediatric Dermatology, 2020, 37, 868-871.	0.5	5
152	Hobnail Hemangioma (Superficial Hemosiderotic Lymphovascular Malformation) in Children. Journal of Cutaneous Medicine and Surgery, 2016, 20, 216-220.	0.6	4
153	Surgical treatment outcomes of infantile hemangioma in children: Does prior medical treatment matter. Pediatric Dermatology, 2018, 35, e418-e419.	0.5	4
154	<scp>ELOVL4</scp> with erythrokeratoderma: A pediatric case and emerging genodermatosis. American Journal of Medical Genetics, Part A, 2021, 185, 1619-1623.	0.7	4
155	Localized Scleroderma. , 2016, , 406-417.e4.		3
156	Dieulafoy lesions and PHACE syndrome. Pediatric Dermatology, 2019, 36, 902-905.	0.5	3
157	Epidermal growth factor receptor deficiency: Expanding the phenotype beyond infancy. Journal of Dermatology, 2020, 47, 898-902.	0.6	3
158	Accuracy of Algorithms to Identify People with Atopic Dermatitis in Ontario Routinely Collected Health Databases. Journal of Investigative Dermatology, 2021, 141, 1840-1843.	0.3	3
159	A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. Journal of the American Academy of Dermatology, 2021, , .	0.6	3
160	Use of topical rapamycin in acral pseudolymphomatous angiokeratoma of children (APACHE): A report of two cases and review of the literature. Pediatric Dermatology, 2020, 37, 877-880.	0.5	2
161	Commentary:Betaâ€blockers and sleep problems. Pediatric Dermatology, 2021, 38, 378-379.	0.5	2
162	Supportive Care: Bathing, Wound Care, Nutrition, Pain and Itch Management, Psychosocial Support, Palliation., 2015,, 653-666.		2

#	Article	IF	CITATIONS
163	Ophthalmic involvement in PHACES syndrome: prevalence, spectrum of anomalies, and outcomes. Journal of AAPOS, 2022, 26, 129.e1-129.e7.	0.2	2
164	Epidermolysis Bullosa: The Pediatricians Role. Current Pediatric Reviews, 2008, 4, 250-257.	0.4	1
165	Acquired Idiopathic Pterygium Inversum Unguis. Clinical Pediatrics, 2010, 49, 394-395.	0.4	1
166	Reply to Frane: Epidermolysis Bullosa Pruriginosa: A Systematic Review Exploring Genotype–Phenotype Correlation. American Journal of Clinical Dermatology, 2015, 16, 339-339.	3.3	1
167	Tropical Skin Diseases in Children: A Reviewâ€" Part I. Pediatric Dermatology, 2016, 33, 253-263.	0.5	1
168	Whole-exome sequencing identifies a homozygous pathogenic variant in TAT in a girl with palmoplantar keratoderma. Molecular Genetics and Metabolism Reports, 2019, 21, 100534.	0.4	1
169	Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. Journal of the American Academy of Dermatology, 2021, 84, 1472-1476.	0.6	1
170	Outcomes of skin cancers in pediatric solid organ transplant patients: A systematic review. Pediatric Transplantation, 2022, 26, e14146.	0.5	1
171	Efficient Gammaâ€Retroviral Transduction of Primary Human Skin Cells Using the EF Peptide as a Transduction Enhancer. Current Protocols, 2022, 2, e353.	1.3	1
172	Sociodemographic characteristics and emergency department visits and inpatient hospitalizations for atopic dermatitis in Ontario: a cross-sectional study. CMAJ Open, 2022, 10, E491-E499.	1.1	1
173	PHACE SYNDROME IS COMMONLY ASSOCIATED WITH UNUSUAL AND POTENTIALLY "SILENT―SEVERE AOR ARCH OBSTRUCTION: THE INTERNATIONAL PHACE SYNDROME REGISTRY REVIEW. Journal of the American College of Cardiology, 2013, 61, E469.	TIC 1.2	0
174	Portâ€Wine Stain–Like Presentation of a Tufted Angioma on the Face. Pediatric Dermatology, 2016, 33, e166-7.	0.5	0
175	A 12-year-old girl with eczema not responding to treatment. Cmaj, 2017, 189, E160-E162.	0.9	0
176	å§ç−±æ€§è¡¨çš®æ¾è§£ç"ç©¶æµç¨‹æ^œžœè¯"å^†å·¥å·(iscorEB)çš"å•鿀§å'Œæœ‰æ•^性. British Journal of l	Dermatolo	g 9 , 2018, 17
177	UNRAVELING INCONTINENTIA PIGMENTI: A COMPARISON OF PHENOTYPE AND GENOTYPE VARIANTS. Paediatrics and Child Health, 2018, 23, e32-e32.	0.3	0
178	A 3-week-old infant with a unilateral facial mass. Paediatrics and Child Health, 2021, 26, 448-450.	0.3	0
179	Reversible alopecia in En Coup de Sabre morphea. Pediatric Dermatology, 2021, , .	0.5	0
180	Connective Tissue Disease. , 2014, , 91-122.		0

ELENA POPE

#	Article	IF	CITATIONS
181	Genodermatoses and Basement Membrane Zone Diseases. , 2017, , 189-202.		O
182	Dermacase. Infantile hemangioma. Canadian Family Physician, 2009, 55, 379-81.	0.1	0
183	Pregnancy in epidermolysis bullosa: longâ€awaited guidelines of care. British Journal of Dermatology, 2021, , .	1.4	O
184	Skin manifestations in pediatric obesity: A prospective cohort study. Pediatric Dermatology, 0, , .	0.5	0
185	Incidence of and Risk Factors for Keratinocyte Carcinoma After Pediatric Solid Organ Transplant. JAMA Dermatology, 0, , .	2.0	O